Related Experiment Video
Updated: May 8, 2026

Visualizing and Quantifying Endonuclease-Based Site-Specific DNA Damage
Published on: August 21, 2021
Loss of IGF-1R impairs DNA-PKcs recruitment to chromatin leading to defective end-joining
Matthew O Ellis1,2,3, Jack V Mills2, Wojciech Niedzwiedz3
1UK-DRI, Department of Clinical Neuroscience, University of Cambridge, Cambridge, England.
Abstract:
The insulin-like growth factor (IGF) axis regulates cancer cell proliferation, growth, invasion, and therapy resistance. Elevated expression of the type 1 IGF receptor (IGF-1R) is linked to radioresistance and biochemical recurrence in prostate cancer, yet the molecular mechanisms underlying IGF-1R-mediated DNA damage responses remain unclear. We investigated the role of IGF-1R in DNA double-strand break (DSB) repair by assessing chromatin recruitment of DNA repair proteins, repair pathway usage, and therapeutic sensitivity in cancer cell models with altered IGF-1R status. Loss of IGF-1R impaired DNA-dependent protein kinase catalytic subunit (DNA-PKcs) localisation to chromatin, resulting in defective non-homologous end-joining (NHEJ) and a compensatory reliance on alternative repair pathways, including microhomology-mediated end-joining (MMEJ). Modulating IGF-1R expression restored radiosensitivity in poly (ADP-ribose) polymerase (PARP) inhibitor-resistant breast cancer cells. IGF-1R inhibition compromises canonical DSB repair and re-sensitises resistant cancer cells to therapy, supporting its potential as a therapeutic strategy in homologous recombination-deficient tumours. Furthermore, IGF-1R mutant cancers may benefit from targeted inhibition of the MMEJ pathway.
Insights
The insulin-like growth factor 1 receptor (IGF-1R) impacts DNA repair, affecting cancer cell therapy resistance. Inhibiting IGF-1R can re-sensitize resistant cancers to treatments like PARP inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The insulin-like growth factor (IGF) axis is crucial in cancer progression and therapy resistance.
- Elevated type 1 IGF receptor (IGF-1R) expression correlates with radioresistance and recurrence in prostate cancer.
- Mechanisms of IGF-1R in DNA double-strand break (DSB) repair are not fully understood.
Purpose of the Study:
- To investigate the role of IGF-1R in DNA DSB repair pathways.
- To assess the impact of IGF-1R on DNA repair protein recruitment and cancer cell sensitivity to therapy.
Main Methods:
- Examined chromatin recruitment of DNA repair proteins in cancer cell models with varying IGF-1R levels.
- Assessed DNA repair pathway usage and therapeutic sensitivity.
- Utilized poly (ADP-ribose) polymerase (PARP) inhibitor-resistant breast cancer cells.
Main Results:
- Loss of IGF-1R impaired DNA-dependent protein kinase catalytic subunit (DNA-PKcs) chromatin localization, hindering non-homologous end-joining (NHEJ).
- Cancer cells showed compensatory reliance on alternative repair pathways like microhomology-mediated end-joining (MMEJ).
- Modulating IGF-1R restored radiosensitivity in PARP inhibitor-resistant breast cancer cells.
Conclusions:
- IGF-1R inhibition disrupts canonical DSB repair, re-sensitizing resistant cancer cells to therapy.
- IGF-1R is a potential therapeutic target, especially in homologous recombination-deficient tumors.
- Targeting MMEJ may benefit cancers with IGF-1R mutations.
Related Concept Videos
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Fixing Double-strand Breaks
Restarting Stalled Replication Forks

